newsfilter
← Latest News
GlobeNewswire·

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

BOSTON and LONDON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payloads for antibody drug conjugates (ADCs), today announced its abstract